Protocol Ledger

NCT04951622 · Phase III · RECRUITING

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Interventional Phase III clinical trial protocol NCT04951622 sponsored by Johnson & Johnson / Janssen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-15 Enrollment: 199 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04951622
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)199 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04951622
Protocol FieldVerified Registry Value
NCT IdentifierNCT04951622
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment199 participants (ESTIMATED)
Registered Start Date2021-07-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI